company background image
39K logo

Centogene MUN:39K Stock Report

Last Price

€0.17

Market Cap

€3.4m

7D

0%

1Y

-84.6%

Updated

24 Dec, 2024

Data

Company Financials

39K Stock Overview

Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. More details

39K fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Centogene N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Centogene
Historical stock prices
Current Share PriceUS$0.17
52 Week HighUS$1.12
52 Week LowUS$0.15
Beta-0.66
1 Month Change0%
3 Month Change12.21%
1 Year Change-84.62%
3 Year Change-96.09%
5 Year Change-98.15%
Change since IPO-98.56%

Recent News & Updates

Recent updates

Shareholder Returns

39KDE HealthcareDE Market
7D0%-2.1%-1.6%
1Y-84.6%15.8%6.8%

Return vs Industry: 39K underperformed the German Healthcare industry which returned 15.8% over the past year.

Return vs Market: 39K underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 39K's price volatile compared to industry and market?
39K volatility
39K Average Weekly Movementn/a
Healthcare Industry Average Movement4.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 39K's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 39K's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006384Kim Strattonwww.centogene.com

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.

Centogene N.V. Fundamentals Summary

How do Centogene's earnings and revenue compare to its market cap?
39K fundamental statistics
Market cap€3.41m
Earnings (TTM)-€35.53m
Revenue (TTM)€48.54m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
39K income statement (TTM)
Revenue€48.54m
Cost of Revenue€30.84m
Gross Profit€17.70m
Other Expenses€53.23m
Earnings-€35.53m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.23
Gross Margin36.46%
Net Profit Margin-73.21%
Debt/Equity Ratio-260.1%

How did 39K perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:54
End of Day Share Price 2024/10/18 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Centogene N.V. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Sung Ji NamBTIG
Erin Wilson WrightCredit Suisse